Table 3.
Hospitalization and/or death due to COVID-19 Cases Demographics by Disease Modifying Therapy.
| FUM1 | S1P | NTZ | OCR | RTX | ||
|---|---|---|---|---|---|---|
| Total2 | 3/39 | 2/43 | 1/36 | 4/77 | 5/35 | |
|
Age (yrs, mean ± SD) (range) |
46.7 ± 12.7 (32-54) |
61.5 ± 0.7 (61, 62) | 60.0 | 43.5 ± 12.6 (31-60) | 40.0 ± 12.4 (23-55) | |
| Race/Ethnicity (n) | White | 1 | 0 | 0 | 0 | 3 |
| Black | 2 | 1 | 1 | 1 | 1 | |
| Other | 0 | 0 | 0 | 0 | 1 | |
| Hispanic | 0 | 1 | 0 | 3 | 0 | |
|
Tx Duration (yrs, mean ± SD) |
3.7 ± 3.2 | 4.0 ± 2.8 | 12.0 | 3.0 ± 2.7 | 5.2 ± 2.3 | |
| Co-morbidity (n)3 | 1 | 2 | 1 | 2 | 1 | |
| BMI ≥30 (n) | 2 | 2 | 1 | 2 | 2 | |
| Assistive Device (n) | Fully Ambulatory | 2 | 0 | 1 | 2 | 2 |
| Impaired | 0 | 0 | 0 | 0 | 0 | |
| Cane | 0 | 0 | 0 | 0 | 1 | |
| Walker | 1 | 1 | 0 | 2 | 0 | |
| Non-ambulatory4 | 0 | 1 | 0 | 0 | 2 | |
| Public Insurance (n) | 1 | 2 | 0 | 0 | 4 |
Legend:
1
Reference group.
2
Total hospitalizations and deaths/total COVID-19 cases.
3
Percentage of patients with any COVID-19-relevant co-morbidity: Cancer, Cardiovascular disease; Cerebrovascular disease; Chronic kidney disease; Chronic liver disease; Chronic lung disease; Diabetes; Hypertension.
4
Non-ambulatory specifies patients who are in wheelchairs or bedbound.
FUM: dimethyl fumarate, diroximel fumarate; S1P: fingolimod, siponimod; NTZ: natalizumab; OCR: ocrelizumab; RTX: rituximab.